Selected article for: "infection second wave and second wave"
Author: Mandal, Avik; Singh, Pritanjali; Samaddar, Arghadip; Singh, Dharmendra; Verma, Manika; Rakesh, Amrita; Ranjan, Rakesh
Title: Vaccination of cancer patients against COVID-19: towards the end of a dilemma
  • Cord-id: 1hkorlks
  • Document date: 2021_7_8
    • ID: 1hkorlks
    Snippet: With the emergence of second wave of COVID-19 infection globally, particularly in India in March–April 2021, protection by massive vaccination drive has become the need of the hour. Vaccines have been proved to reduce the risk of developing severe illness and are emerging as vital tools in the battle against COVID-19. As per the GLOBOCAN database, nearly 19.3 million new cancer cases have been reported in 2020 globally, which posed a significant challenge to health care providers to protect su
    Document: With the emergence of second wave of COVID-19 infection globally, particularly in India in March–April 2021, protection by massive vaccination drive has become the need of the hour. Vaccines have been proved to reduce the risk of developing severe illness and are emerging as vital tools in the battle against COVID-19. As per the GLOBOCAN database, nearly 19.3 million new cancer cases have been reported in 2020 globally, which posed a significant challenge to health care providers to protect such large number of ‘vulnerable’ patients from COVID-19. Nevertheless, a considerable degree of doubt, hesitancy and misconceptions are noted regarding the administration of vaccines particularly during active immuno-suppressant treatment. This review article highlights the added vulnerability of cancer patients to the COVID-19 infection and has explored the immunological challenges associated with malignancy, anticancer treatment and COVID-19 vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12032-021-01540-8.

    Search related documents:
    Co phrase search for related documents
    • aberrant expression and adaptive innate: 1, 2, 3, 4
    • aberrant expression and lung cancer: 1, 2, 3, 4, 5, 6
    • aberrant expression and lung injury: 1, 2, 3, 4
    • aberrant expression and lymph node: 1
    • active malignancy and acute sars respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active malignancy and lung cancer: 1
    • active malignancy and lung injury: 1
    • active treatment and acute illness: 1, 2, 3, 4
    • active treatment and acute sars respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
    • active treatment and long term short: 1, 2, 3, 4
    • active treatment and longitudinal cohort: 1, 2, 3, 4
    • active treatment and longitudinal cohort study: 1, 2, 3, 4
    • active treatment and low seroconversion rate: 1
    • active treatment and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • active treatment and lung injury: 1, 2, 3, 4, 5, 6, 7
    • active treatment and lymph node: 1